Lavipharm S.A. (ATH:LAVI)

Market Cap	260.33M +117.0%
Revenue (ttm)	62.58M +18.2%
Net Income	5.99M -33.4%
EPS	0.03 -34.7%
Shares Out	169.04M
PE Ratio	52.74
Forward PE	n/a
Dividend	0.02 (1.30%)
Ex-Dividend Date	n/a

Volume	402,205
Average Volume	304,279
Open	1.534
Previous Close	1.532
Day's Range	1.510 - 1.560
52-Week Range	0.734 - 1.570
Beta	1.00
RSI	72.49
Earnings Date	Apr 23, 2026

About Lavipharm

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1911
• Employees: 282
• Stock Exchange: Athens Stock Exchange
• Ticker Symbol: LAVI

Financial Performance

In 2025, Lavipharm's revenue was 62.58 million, an increase of 18.20% compared to the previous year's 52.95 million. Earnings were 5.99 million, a decrease of -33.36%.